Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $10
Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
Follow the latest OptimizeRx Corporation (OPRX) news and market headlines alongside the live OPRX price. Stay informed on what's moving OPRX.
Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
OptimizeRx beat Q3 earnings and sales estimates but cut FY2026 revenue guidance; shares fell 17.3% as analysts lowered price targets.
Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market cap stands
B. Riley Securities analyst Josh Nichols reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.5.
Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session. ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their outstanding shares is
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $12 to $11.
OptimizeRx (OPRX) beat Q3 2026 earnings expectations with $0.2 EPS versus consensus of $0.18, though revenues declined year-over-year to $21.62M from $26.07M. Despite beating estimates, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The stock has underperformed the S&P 500 by 33.6% year-to-date. Smith Micro Software (SMSI) is expected to report a quarterly loss of $0.11 per share.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to OPRX, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.